Jennerex, a long-time developer of therapeutics for cancer patients, has branched into treatments targeting oncolytic viruses — viruses that specifically infect cancer cells — and it just raised $5.1 million in third-round funding to fuel its efforts. Based in San Francisco, the company has kept the round open, hoping to raise more before it closes next month. It previously raised an $8.3 million second round last fall, reports PE Hub. It has not disclosed the identity of its investors.
Jennerex plans to use its new financing to continue pushing its lead product through clinical trials. It is currently in phase three trials for liver cancer, phase two trials for colon cancer and its first set of trials for lung cancer.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more